Q2 2022 Owlet Inc Earnings Call

and uncertainties relating to future events and or the future financial performance of the company.

Actual results could differ materially from those anticipated in these four button statements.

The risk factors that may affect results are detailed in the company's most recent public filings with the U.S. Securities and Exchange Commission, including its quarterly report filed May 13.

2022 and other reports filed with the SEC, which can be found on its website at investors.owlacare.com or on the SEC website at www.SEC.gov.

The information provided in this conference call speaks only as of today's live call. I will let this claim to any intention or obligation, except as required by law, to update or revise any information, financial projections, or other forward-looking statements, whether because of new information, future events, or otherwise.

Please also note that Owlet will refer to certain non-GAAP financial information on today's call.

You can find reconciliations of these non-GAAP financial measures to the most comparable GAAP measures in the company's earnings press release, which is also available on the company's quarterly results page of its website.

I will now turn the call over to Kurt.

Thank you, Mike. Good afternoon to all who are joining us today. As always, we're grateful to you and to the millions of parents who continue to root for and support ALLET as we work to build a connected nursery ecosystem.

My remarks this afternoon will focus on our results for the second quarter and yearly dates and are signed forward as we work to deliver on our vision to every baby and every parent.

We remain steadfast and committed to that, and we're proud of the business we've built.

Later in this call, I'll detail our approach for the remainder of the year, how we're navigating current headwinds and updates we're making to our business as we work toward profitability.

A look at the second quarter of 2022. How it generated net revenues of $18.3 million, which fell short of the guidance we shared in our last earnings announcement.

We did not achieve the gross billing results as we expected in Q2, largely due to two main reasons.

I'll first address the outlet-specific dynamics and second discuss the macroeconomic commitment to Montgomery.

Since we'll be referencing this throughout the call, for a quick baseline definition, we refer to sell in as a measure of the number of units retailers purchase from outlet to stock their shelves and sell through when the unit is actually sold to the end consumer.

Q2 was our first full quarter of Dream product availability online and in store at all of our retail partners.

Solid Online, and with our Amazon distribution partners.

As a reminder, following the launch of the Dream product in January , much of the initial sell-in and online in-store availability of our Dream products took place late in Q1.

From Q1 to Q2, we experienced over 40% growth in sell-through units for our dream products across our channel. While this rate of growth was good from an initial product launch standpoint, it was a slower pace of sell-through than we had expected and consequently we had more aggressive Q2 sell-in-sales expectations.

In addition, along with many consumer brands, in Q2, Allard began experiencing the effect of macro headwinds with retailers, adjusting their projections and ordering cadence in terms of weeks of supply as they began to defensively position their balance sheet compared to last year.

This combination of factors resulted in lower than expected growth billings for the second quarter of $22.7 million.

With the second quarter revenue results and current macroeconomic factors in mind, we're realigning our operating plan for the second half of 2022.

I'll let three primary areas of focus are first achieving strong sell-through of our core products including our stock and camera line

Second, making strides in our medical device submission.

and finally, efficiently managing our balance sheet and expenses to reach breakeven adjusted EVA.

First, our focus on achieving strong sell-through of our core products to drive top line revenue.

We are seeing encouraging signs of our underlying strategy for our dream products taking hold that affirm our product market fit and demand. The sell-through rate over the past few months is similar to and starting to pace ahead of the volume we did in 2020.

That is the same business we took public, so we are confident in our ability to continue our brand leadership in the connected nursery ecosystem and market fit for the value proposition of our dream product.

Additionally, we started the year with a brand new product. We now have an average of four plus stars on all of our products, which is extremely important to ongoing consumer sales. Dream Duo was recently named a best baby monitor by CBS News, and the number of expecting parents adding Dream products to their baby registry continues to grow.

post purchase metrics including that promoter score, remain strong and rival what we previously saw with the SmartStop.

We continue to drive new levels of marketing support and retail partnership with the Al DNAX

Our recent Amazon Prime Day in July was ALOT's best ever, where the number of units sold were double our internal forecast and ALOT ranks as the number one baby monitor on Amazon in the US.

We're also expanding to about 1,200 Walmart doors and adding the Dream Duo as a product offering to 600 existing Target doors.

Internationally, we're pleased with the progress we've made in launching our products in the parts of Asia, the South Korea market opening this month.

Year-to-day, international growth feelings are up over 60%.

Combined, we believe these are leading indicators of a solid foundation of sell-through that we build on with consumers and retailers through the remainder of the year. In July , we launched our newest technology domestically, including the next generation nursery outlet Campu and the predictive sleep technology tool.

We're continuing to load into our retail partners through the remainder of Q3, and Q2 will officially launch in international markets this quarter as well.

The dream platform we're building today for our sock line is part of what we will leverage in our medical devices, expanding on our core technologies to accelerate adoption, and add use cases for our monitoring technologies.

Our team is working on several medical device submissions, including in the US and internationally.

Notably, we plan to submit our 510K application to the FDA for our baby-sized device in the coming weeks.

Babyset is intended to be a prescription product for use with sick babies under the care of a physician and will address the most vulnerable population.

With existing CPT codes available, we believe the BabyTac could be reimbursable, which will also improve accessibility to this critical technology.

We have also recently aligned with FDA on our submission for our software as the medical device features.

as an over-the-counter product that offers heart rate and oxygen notifications on top of the existing DreamSox sleep tracking capabilities.

We believe we are on track to submit our application in Q4.

Finally, the international clearances are part of our measure of success as we work towards admissions in Europe .

Adding cleared medical devices to our offering will further enhance the Allen Value Proposition and better empower parents to provide care at home.

I believe we have the right team in place to execute against these submissions, and we will continue to report on these milestones in future calls.

The third area of focus for ALLEX is to efficiently manage our operating model as we navigate the sell-in and sell-through demand trends effectively with our retail partners within macroeconomic headlines.

and as we resolve the working capital hangover from the FDA warning letter process.

Prior to taking our company public, we were driving lean leverage in our business and adapted our investment strategy when we went public last July .

In 2021, and the first half of 2022, we invested in scaling our business, marketing spend, and future investment in our product portfolio.

Based on macroeconomic conditions in the market, we are adjusting our 2022 operating plan to reduce our operating costs and accelerating our plans to drive the business to break even adjusted EBITDA in 2023.

Toward these goals, in late July , we implemented a restructuring program to streamline our organizational structure, reducing operating expenses and managing and conserving our cash resources.way through the knowledge of the artistsasse and we join in a sharing of these assets. In turn, drawing on the design and the AK

For the second half of 2022, we're focusing on being the baby monitor of choice for families, which includes further enhancements and improvements to the DreamSox and adding features that make this the monitor for every baby.

This means we're elongating our launch timing for some new product portfolio initiatives like Smart Grid. However, it remains an important part of our future roadmap.

We believe this focus on operating efficiency will allow us to better control our destiny.

and be more nimble in the face of the changing economy and business environment.

We're optimistic these pivots will put the business on track for profitability sooner as we build on the foundation of our core technologies, accelerating adoption and expanding use cases with medical devices.

Finally, I want to take a moment to thank Mike Abbott for his years of service at outlet. Mike announced today that he's resigning from his role as president and board member at outlet to spend more time with his family and pursue new opportunities.

Mike joined Allyn over four and a half years ago, and in his time here, he was instrumental in our expansion to a global public company.

We wish him well in his next chapter.

I'm grateful for a passionate team that's been dedicated to improving lives and helping parents navigate this incredibly important part of their journey.

How it is empowering parents with information they need to better deliver care at home, and our vision is that every family has access to the tools and technology they need to keep babies safe, healthy, and happy. Thank you again for your continued support of the outlet and our mission. I look forward to sharing more updates and future calls. Kate, I'll now turn the time over to you.

Thank you and good afternoon everyone. Turning to our Q2 results.

Gross buildings for the quarter were $22.7 million below our expectations for the quarter. As Kurt stated, this is our first full quarter for our dream products in the marketplace and we did not see the anticipated rate of sell-in and sell-through following our successful launch into retailers in Q1.

In addition, retailers began to reduce their inventory productions as they worked to reposition their balance sheets more defensively for macro headwinds.

Q2 product promotions and discounts were $2.5 million, relatively consistent with the prior year. This included $2.3 million associated with our July Amazon Prime Day.

Return adjustments for Q2 2022 were $1.8 million, a 41% reduction for the first quarter and in line with the prior year.

Direct to consumer return rates normalize the levels similar to our Smart Stock products, which we believe is driven by consumers better understanding the dream value proposition.

Within this, approximately $1 million was for adjustments for FDA return to vendor activity associated with our Smart Dot product.

In summary, Q2 net revenues were $18.3 million, including the impact of adjustments in the

such as promotions, discounts, and other allowances.

Cost of goods sold in Q2 was $11.7 million and gross profit was $6.6 million.

Q2 gross margin was 36.1% compared to 54.2% gross margin in the prior year.

Compared to the same period in 2021, our gross margin was impacted by macroinflationary pressures, including product costs, shipping, and fulfillment. In addition, promotional discounts and returns remained at similar levels to the prior year.

Operating expenses for the second quarter 2022 were $27 million compared to $19.4 million for the same period in 2021.

The increase in year-over-year operating expenses was primarily for planned increases in spending associated with the scaling of the business.

public company costs, and stock-based compensation.

In July , at a company implemented a restructuring program to streamline the company's organizational structure, reduce operating expenses, and manage and conserve cash resources to strive for profitability.

As part of the restructuring program, we commenced a workforce reduction of approximately 74 employees that is expected to be substantially completed in Q3.

and we expect to incur costs of approximately 1.1 million, consisting primarily of severance, one-time termination benefits, and other related costs.

As a result of the restructuring actions, we expect to reduce run rate operating costs, excluding share-based compensation and incentive compensation to approximately $15 million to $19 million per quarter, exiting the fourth quarter of 2022.

Operating loss and net loss for the second quarter of 2022 were $20.4 million and $11.7 million respectively as compared with $5.9 million operating loss and $5.3 million net loss for the same period in 2021.

Q2 adjusted EBITDA loss was 16.7 million compared to adjusted EBITDA loss of 2.6 million for the same period in 2021.

Turning to the balance sheet, cash and cash equivalents as of June 30 were approximately 37 million.

Accounts receivable are $24 million, up $7.4 million sequentially from $16.6 million in Q1.

Inventory at the end of Q2 was 29.4 million, up 4.7 million sequentially from 24.7 million in Q1.

Nearly all return authorizations for RTB was closed for retailers at the end of the second quarter.

The company is in the process of working with its customers to apply liabilities against outstanding invoices where applicable.

From a working capital perspective, we plan to heavily utilize existing inventory on hand.

With regards to our financing arrangements, we did not meet our revenue covenant for the second quarter, which was waived by Silicon Valley Bank.

As part of our waiver agreement, our liquidity covenant was reduced to $22.5 million and our line of credit was reduced to $5 million.

The waiver agreement is intended to function as a bridge arrangement, and we're actively working with FVBA on further restructuring our loan and line of credit, including amending future financial covenants, which we expect to complete during the third quarter.

All of our outstanding bar earnings with SBB are represented as a current liability on the June 30, 2022 balance sheet, including in our second quarter earnings release.

Looking ahead, as Kurt outlined, we have three primary areas of focus.

Achieving sell-through of our core products, making strides in our medical device submissions.

and officially managing our operational plans towards breakeven and profitability.

While we continue to believe in and invest in our strong relationships with our retail partners.

We are entering the back half of the year with caution, giving retailers signals on reducing inventory and managing balance sheets more defensively and cautionary consumer spending in this macro environment.

Given our reduced forecasting visibility, we are not providing revenue guidance for Q3.

We are planning for Q3 operating expenses to be lower sequentially, reflecting operating taxes that began in July .

Operator, let's open it up for questions.

Thank you. Ladies and gentlemen, if you would like to ask a question, please press star, then 1 on your telephone keypad. If you wish to withdraw your question, please press star, followed by 2. When preparing to ask your question, please ensure your phone is unmuted locally.

Our first question comes from Charles Rie from Cowan. Charles your line is open.

Hi, this is Steve Braun on For Charles.

Just had a quick question on the guidance that you just provided on the year. So it seemed like you're a little bit more cautious on consumer spending and the outlook for the rest of 2022, but given where I guess we've been seeing some moderation in the producer price index and also inflation this month, I guess like can you unpack some of the assumptions there and kind of like what's going into that outlook? Thank you.

Yeah, do you want to pick that one?

Yeah, sure. I think part of what we try to provide is some of the discussion is we launched our new products at the beginning of the year, which we're really excited about. And what we've been able to manage is really the perception and adoption of that product, so the MPS scores, the consumer ratings, and the overall transition to the Dream product platform. That fell in for us really happened late in Q1.

So I think that just given both of those dynamics, we're entering the bad cap with optimism around our portfolio, but also with the caution with the macro environment that other retailers and the consumer spending index are presenting. So we don't have a unique point of view on it, but we're sharing that caution that others express.

Okay, thank you.

Thank you.

Our next question comes from John Babcock from Bank of America. John , your line is open.

Thanks for taking my questions. I guess to start out on the demand front, could you talk about when things started to slow? I think we're hearing from others, at least on the consumer front, that it seemed like most of that began in June . But just kind of curious to hear what you're seeing. And also, if you could talk about trends, how that's continued in July and into August , that would be helpful.

Thanks, John . It's been kind of a unique year for Outlet, right, because we were out of the market for a quarter in Q4 of last year where we weren't selling products.

We launched the Dreamstock in Q1 and it took us a full quarter to get back to market, get back into all of our stores and all of our online channels. And then Q2 we were really measuring sell-through growth. I think our hope was we'd be moving at a faster clip. We'd be back in the market faster. The sell-through would ramp faster. But what I would say is overall in terms of...

you know, just general sell-through growth. We've seen really good improvement Q1 to Q2, and then July , as we've noted, was one of our – was our best Prime Day ever, and we saw a really good sell-through in July as well. So there's kind of two stories here, but to your point, in June we did have some retailers pull back on their forecast and reduce the amount of inventory that they were willing to hold as part of our expansion activities and growth with them.

And we've heard kind of similar sentiment moving forward that they're being a little bit more cautious about how much inventory they're going to hold and how that's flowing. So hopefully that answers your question. There's sort of good momentum because we're coming back to market and we're seeing that. But at the same time there's some of these macro pressures that – –

that are more coming from the retailers than the consumers themselves at this point in time.

Just to make sure on the inventory front, what are you guys doing to manage that? Are you adjusting any sort of production schedules? Are inventories generally in good shape? What can you comment there? What can you comment there?

Yeah, we're working with our partners to make sure that we're bringing the inventory down. That's one of our goals, to bring it more in line with where sell-through and selling is today. And that's part of the activity. We're also working with our partners to continue to sell through with the product and to grow the business and to grow that sell-through. But yeah, to your point, we are working to reduce our inventory level.

Okay, and then just the last question I have, at least I think so, is generally, you talked about wanting to get to break even. How quickly could that occur? And also, I would assume this is going to have some impact on growth. So on that front, I was just wondering, at this point, you're waiting for the macro situation to improve before wrapping up investments again or how you're thinking about that. Okay, thank you.

Yeah, Gabe, you want to take that?

So, John , really the investments that we were making in the first half that were contributing to the run rate of operating expense were investing in the product portfolio for next year. So as we talked about, for example, the bringing out our smart credit will elongate the time to market there. Some of the other investments would correlate to, let's just say, discretionary spending, but it's just, you know, you know, a real wildland pattern We might need to get more

in that range of $15 to $19 million in operating expense, excluding the stock-based comp. In terms of bringing in that kind of break-even and getting to profitability, we had said that we were targeting kind of exiting 2023. And as long as we maintain that run rate will be much earlier in the year next year. And that we'll see how things moderate with the macro. And when we're able to turn back on.

in terms of marketing and sales. We'll continue to look at that. But I think that what's important is that we were able to refresh our product portfolio this year with the Dream platform, both in terms of our SOC and CAM. And also, as we talked about with our regulatory clearances, we have a couple of those processes underway still through the end of this year. And then those will be on track as well. So a number of the things that we have in front of us are with our fresh portfolio.

tools that we converted for Sonya. Yeah so the inventory that we brought back in, some of the comments that we made that we believe that we're through that process of return to vendor and so we're selling that back into the market or we have that in inventory on our balance sheet but that process is we believe we're through it or nearly all the way through it.

Thank you.

Thank you.

Our next question comes from Jim Silva from Citigroup. Jim your line is open.

Thank you so much. There was some commentary in the press release that gross margins were impacted by higher returns. Can you walk us through, because I thought the returns were more kind of October , November , December of last year, so maybe my memory is off on that or maybe there's additional factors and it sounds like is that the end of it or could those kind of continue on?

So the return rate that we saw in Q2 as it relates to the run rate of our product or general sales returns actually was back to where our original product was. So on a sequential basis, that rate actually declined. Where we had costs related to returns was around the return to vendor program, so about 1.1 million.

against gross sales was related to the Return to Vendor program that we won't see again. So that's part of the rework program, and that hit our gross margin in the quarter.

Okay, and then did I hear on your last answer to the prior question you said

breakeven, is goal for 2023, is that like exiting or full year in totality or how should we think about that timing and comment? We'll try to bring it earlier into 2023 and I think our primary goal is to reduce operating expenses considerably in the back half of this year. We just took our action over the last couple of weeks and we'll look forward to updating you on that timeline.

in November , but certainly the actions that we took in the changes in the product portfolio will help us accelerate that much earlier into 2023.

Okay, and that profitability definition, is that like earnings per share or EBITDA, or how did you define profitability or cash flow? What Et

Okay, thank you so much.

Thank you. Ladies and gentlemen, currently we have no further questions. Therefore, I would like to hand back to Kurt Workman, CEO of the company, for any closing remarks. Kurt, please go ahead.

Yeah, thank you. I just want to kind of reiterate our commitment to our mission of empowering parents to really give care at home. I think Alice does that in such a unique way. It's what motivates our employees and our partners, and the commitment that we see there is incredible. We're excited about the progress we're making with DreamSOC and the growth in DreamSOC. We look forward to putting our FDA submissions in very soon, and I believe the business is in a much healthier track with the restructuring that Kate mentioned.

The.